

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Dapagliflozin for treating chronic kidney disease

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No equality issues were raised during the scoping process. |

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| A patient group submission highlighted that: <ul style="list-style-type: none">Chronic kidney disease disproportionately affects people from ethnic minority groups and lower socioeconomic backgrounds.People from these groups are also more likely to have chronic kidney disease that progresses quicker to kidney failure and die earlier.Some ethnic minority groups may be more sensitive to the combined effects of proteinuria and hypertension than other ethnic groups.Younger people (<55 years) with diabetes and CKD are at higher risk of rapid progression of CKD compared with older people (>65 years) and need closer monitoring, management of risk factors and early specialist review to delay disease progression. |

It was agreed that these equality issues could not be resolved by technology appraisal guidance.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Some discussion has been described in section 1 of the final draft guidance.
Cost comparisons include only limited discussion of issues.

Approved by Associate Director (name):Janet Robertson.....

Date: 22 May 2025